Mangafodipir trisodium 锰福地吡三钠; MnDPDP|cas:140678-14-4|西域试剂

Mangafodipir trisodium 锰福地吡三钠; MnDPDP,99.82%

产品编号：Bellancom-B0993| CAS NO：140678-14-4| 分子式：C₂₂H₂₇MnN₄Na₃O₁₄P₂| 分子量：757.32

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-B0993	￥1200.00	杭州北京（现货）
Bellancom-B0993	￥3500.00	杭州北京（现货）
Bellancom-B0993	￥5500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Mangafodipir trisodium 锰福地吡三钠; MnDPDP

产品介绍

Mangafodipir trisodium (MnDPDP) 是肝细胞特异性造影剂，也是一种有效的 CIPN (化疗诱导的周围神经通路)和其他细胞氧化应激引起的条件抑制剂。Mangafodipir trisodium 对化疗的肿瘤杀伤活性无负干扰。

生物活性

Mangafodipir trisodium (MnDPDP), hepatocellular-specific contrast agent, is an efficacious inhibitor of CIPN (chemotherapy-induced peripheral neuropath) and other conditions caused by cellular oxidative stress. Mangafodipir trisodium shows no negative interference with the tumoricidal activity of chemotherapy.

体外研究

Mangafodipir trisodium (40, 200 和 1000 μM) 抑制 H₂O₂ 对 HGrC 细胞活力的影响。
Mangafodipir trisodium (200 和 1000 μM) 减少顺铂诱导的 HGrC 细胞凋亡。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Mangafodipir trisodium (10 mg/kg；腹腔注射，一次) 显示出对顺铂和紫杉醇引起的小鼠卵巢损伤的保护作用。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female CD-1(ICR) Mice with cisplatin- and paclitaxel-induced ovarian damage
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; 10 mg/kg, once
Result:	Attenuated the loss of primordial follicles, reduction of secondary follicles and increase of antral follicles. Prevented the change of primary follicles caused by cisplatin and paclitaxel. Reduced the increasing of cleaved caspase-3 levels caused by cisplatin and paclitaxel.

体内研究

Mangafodipir trisodium (10 mg/kg；腹腔注射，一次) 显示出对顺铂和紫杉醇引起的小鼠卵巢损伤的保护作用。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female CD-1(ICR) Mice with cisplatin- and paclitaxel-induced ovarian damage
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; 10 mg/kg, once
Result:	Attenuated the loss of primordial follicles, reduction of secondary follicles and increase of antral follicles. Prevented the change of primary follicles caused by cisplatin and paclitaxel. Reduced the increasing of cleaved caspase-3 levels caused by cisplatin and paclitaxel.

性状

Solid

溶解性数据

In Vitro:

H₂O : 33.33 mg/mL (44.01 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.3204 mL	6.6022 mL	13.2045 mL
5 mM	0.2641 mL	1.3204 mL	2.6409 mL
10 mM	0.1320 mL	0.6602 mL	1.3204 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶